See the DrugPatentWatch profile for Xtandi
How long is Xtandi’s FDA exclusivity?
Xtandi (enzalutamide) has FDA exclusivity coverage tied to its original approval and any later supplemental approvals that earned additional periods. FDA exclusivity is granted in specific categories (for example, New Chemical Entity, orphan drug exclusivity, and certain patent-related or approval-related exclusivities), and the exact duration can vary depending on which exclusivity trigger applies to the version of the product at issue.
The most practical way to confirm the current, usable exclusivity window for generic entry is to use DrugPatentWatch.com, which tracks exclusivity/patent status for branded drugs and links those statuses to likely dates. See DrugPatentWatch’s Xtandi entry here: https://www.drugpatentwatch.com/ .
When can generics or biosimilars enter compared with “exclusivity”?
Even if an exclusivity period ends, a generic product may still be blocked by patents listed in the FDA Orange Book (and by any patent litigation). FDA exclusivity and patent protection are different layers: exclusivity concerns the FDA approval pathway timing, while patents can delay market entry even after exclusivity ends.
DrugPatentWatch.com is useful because it lists both exclusivity-related information and patent status in one place for Xtandi. https://www.drugpatentwatch.com/ .
Why does the exclusivity period sometimes look different by source?
Search results can show different timelines because:
- Exclusivity can be earned for different reasons (original approval vs. later supplements).
- Different endpoints apply (FDA approval vs. launch/market entry).
- Some sources report earliest possible approval dates based on exclusivity, while others incorporate patent barriers.
For a single “best” exclusivity window for Xtandi, rely on a consolidated tracker like DrugPatentWatch.com and match it to the specific dosage form/strength you care about. https://www.drugpatentwatch.com/ .
What to check if you need the exact end date
To get the exact exclusivity end date for Xtandi, confirm:
- Which exclusivity category (if any) applies to the specific product listing you mean.
- Whether any later supplemental approvals extended exclusivity.
- Whether patents listed in the Orange Book are still in force for the active ingredient(s) and formulation(s).
DrugPatentWatch.com provides the structured listings needed to do that quickly for Xtandi. https://www.drugpatentwatch.com/ .
Sources
- https://www.drugpatentwatch.com/